EA just announced that it wouldn't be focusing on the Star Wars Battlefront series in the coming future. Now we need another ...

The biotech raised $113 million in an institutional share placement last year to fund phase 3 development of sozinibercept, a VEGF 'trap' compound that targets two forms of the protein – VEGF-C ...